A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia

Psychiatry Research

Volumn 177, Issue 3, 2010, Pages 286-293

  Meltzer, Herbert Y ^a   Bobo, William V ^a   Lee, Myung A ^a   Cola, Philip ^a   Jayathilake, Karuna ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Clozapine; Efficacy; Relapse; Schizophrenia; Treatment resistant; Typical neuroleptics; Weight gain

Indexed keywords

AMOXAPINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MOLINDONE; PERPHENAZINE; THIORIDAZINE; TIOTIXENE;

ADULT; AGRANULOCYTOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE, ATTEMPTED; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952673653     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.02.018     Document Type: Article

References (65)

1. Allison D.B., Mentore J.L., Heo M., Chler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999, 156:1686-1696.
2. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, American Psychiatric Press, Washington, DC. 3rd ed., revised (DSM-IV.
3. Andreasen N. The Scale for the Assessment of Negative Symptoms (SANS) 1981, University of Iowa, Department of Psychiatry, Iowa City, Iowa.
4. Andreasen N. The Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa, Department of Psychiatry, Iowa City, Iowa.
5. Ascher-Svanum H., Zhu B., Faries D., Lbloom R., Swartz M., Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006, 6. available online at: www.biomedcentral.com/1471-244X/6/8.
6. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J., Kunz M., Chakos M., Cooper T.B., Horowitz T.L., Lieberman J.A. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizohprenia or schizoaffective disorder. American Journal of Psychiatry 2002, 159:1018-1028.
7. Buchanan R.W. Clozapine: efficacy and safety. Schizophrenia Bulletin 1995, 21:579-591.
8. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with TR schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 2001, 158:518-526.
9. Conley R.R., Love R.C., Kelly D.L., Bartko J.J. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. American Journal of Psychiatry 1999, 156:863-868.
10. Czobor P., Volavka J., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J., Cooper T.B., Chakos M., Lieberman J.A. Antipsychotic-induced weight gain and therapeutic responses: a differential association. Journal of Clinical Psychiatry 2002, 22:244-251.
11. Davis J.M., Chen N. Does response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology 2004, 24:192-208.
12. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003, 60(6):553-564.
13. Ekblom B., Haggstrom J.E. Clozapine (Leponex) compared with chlorpromazine: a double-blind evaluation of pharmacological clinical properties. Current Therapeutic Research, Clinical and Experimental 1974, 16:945-957.
14. Endicott J., Spitzer R.L. A diagnostic interview. The Schedule for Affective Disorders and Schizophrenia. Archives of General Psychiatry 1978, 35:837-844.
15. Essock S.M., Hargreaves W.A., Covell N.H., Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacology Bulletin 1996, 32:683-697.
16. Faltus F., Hynek K., Dolezalova V., Kumnickova Z., Zemek P. Experience in the treatment of schizophrenia with clozapine. Activitas Nervosa Superior (Prague) 1973, 15:95.
17. Fischer-Cornelssen K.A., Ferner U.J. An example of European multicenter trials: multispectrral analysis of clozapine. Psychopharmacology Bulletin 1976, 12:34-39.
18. Gerlach J., Koppelhus P., Helweg E., Monard A. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatrica Scandinavica 1974, 50:410-424.
19. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: a systematic overview and meta-regression analysis. British Medical Journal 2000, 321:1371-1376.
20. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338 1976, 534-537. United States Department of Health, Education, and Welfare, Washington, DC. W. Guy (Ed.).
21. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 1993, 34:702-712.
22. Harvey P.D., Meltzer H., Simpson G.M., Potkin S.G., Loebel A., Siu C., Romano S.J. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophrenia Research 2004, 66:101-113.
23. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984, 10:338-398.
24. Hippius H. A historical perspective of clozapine. Journal of Clinical Psychiatry 1999, 60(suppl 12):22-23.
25. Honigfeld G., Patin J. A two-year clinical economic follow-up of patients on clozapine. Hospital and Community Psychiatry 1990, 41:882-890.
26. Honigfeld G., Patin J., Singer J. Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Advances in Therapy 1984, 1:77-97.
27. Jennrich R.I., Schluchter M.D. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986, 42:805-820.
28. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 2006, 63:1079-1087.
29. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorge M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008, 371:1085-1097. EUFEST Study Group.
30. Kane J., Honigfeld G., Singer J., Meltzer H.Y. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine/benztropine. Archives of General Psychiatry 1988, 45:789-796. the Clozaril Collaborative Study Group.
31. Kane J.M., Woerner M., Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology 1988, 8 (suppl 4:52S-56S.
32. Keefe R.E., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry 2007, 64:633-647. CATIE Investigators, the Neurocognitive Working Group.
33. Kirk R.E. Experimental Design 1982, Brooks/Cole, Belmont, CA.
34. Leadbetter R., Shutty M., Pavalonis D., Vieweg V., Higgins P., Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. American Journal of Psychiatry 1992, 149:68-72.
35. Lee M.A., Thompson P.A., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. Journal of Clinical Psychiatry 1994, 55 (suppl B:82-87.
36. Lee M.A., Jayathilake K., Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophrenia Research 1999, 37:1-11.
37. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry 2003, 160:1209-1222.
38. Lieberman J.A., Ma J., Alvir J., Woerner M., Degreef G., Bilder R.M., Ashtari M., Bogerts B., Mayerhoff D.I., Geisler S.H., Loebel A., Levy D.L., Hinrichsen G., Szymanski S., Chakos M., Koreen A., Borenstein M., Kane J.M. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophrenia Bulletin 1992, 18:351-371.
39. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., Ji Z., Kock G., Hamer R.M. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmcology 2003, 28:995-1003.
40. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005, 353:1209-1223. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
41. Littell R.C., Milliken G.A., Stroup W.W., Wolfinger R.D. SAS System for Mixed Models 1996, SAS Institute, Cary, NC.
42. Margolese H.C., Choinard G., Kolivakis T.T., Beauclair L., Miller R., Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Canadian Journal of Psychiatry 2005, 50:703-714.
43. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K., Investigators C.A.T.I.E. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 2006, 163:600-610.
44. Meltzer H.Y. Treatment resistant schizophrenia-the role of clozapine. Current Medical Research Opinion 1997, 14:1-20.
45. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999, 25:233-256.
46. Meltzer H.Y., Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia:impact on risk-benefit assessment. American Journal of Psychiatry 1995, 152:183-190.
47. Meltzer H.Y., Lee M., Cola P. The evolution of treatment resistance: biological implications. Journal of Clinical Psychopharmacology 1998, 18:5S-11S.
48. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., An R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.P., Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 2003, 60:82-91. International Suicide Prevention Trial Study Group.
49. Meltzer H.Y., Perry E., Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophrenia Research 2003, 59:19-27.
50. Meltzer H.Y., Bobo W.V., Roy A., Jayathilake K., Chen Y., Ergtugrul Y., Yagcioglu A.E.A., Small J.G. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Journal of Clinical Psychiatry 2008, 69:274-285.
51. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(suppl 1):1-93.
52. Newcomer J.W., Haupt D.W. The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry 2006, 51(8):480-491.
53. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychological Reports 1962, 10:799-812.
54. Reilly J.L., Harris M.S., Khine T.T., Keshavan M.S., Sweeney J.A. Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. Biological Psychiatry 2007, 62:818-821.
55. Rodova A., Svastka J., Nahunek K., Ceskova E. A blind comparison of clozapine and perphenazine in schizophrenics. Activitas Nervosa Superior (Prague) 1973, 15:94-95.
56. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., Fye C., Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New England Journal of Medicine 1997, 337:809-815.
57. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scinavica 1970, 212 (suppl):11-19.
58. Simpson G.M., Varga E. Clozapine-a new antipsychotic agent. Current Therapeutic Research, Clinical and Experimental 1974, 16:679-686.
59. Surguladze S.A., Chu E.M., Evans A., Anilkumar A.P., Patel M.X., Timehin C., David A.S. The effect of long-acting risperidone on working memory in schizophrenia: a functional magnetic resonance imaging study. Journal of Clinical Psychopharmacology 2007, 27:560-570.
60. Tiihonen J., Lönnqvist J., Wahlbeck K., Timo Klaukka T., Niskanen L., Tanskanen A., Haukka J. Mortality in schizophrenia: an 11-year follow-up study of the total Finnish population (FIN11 Study). Lancet 2009, 374(9690):620-627.
61. Wahlbeck K., Cheine M., Essali A., Adams C. Evidence of clozapine's effectiveness in schizophrenia: systematic review and meta-analysis of randomized trials. American Journal of Psychiatry 1999, 156:990-999.
62. Wahlbeck K., Cheine M., Essali A. Clozapine versus typical neuroleptic medications for schizophrenia. Cochrane Database of Systematic Reviews 2000, 2. CD000059.
63. Woerner M.G., Robinson D.G., Alvir J.M., Sheitman B.B., Lieberman J.A., Kane J.M. Clozapine as a first treatment for schizophrenia. American Journal of Psychiatry 2003, 160:1514-1516.
64. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. Meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology 2005, 8:457-472.
65. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics-dose effects and comparison to practice effects. Schizophrenia Research 2007, 89:211-224.